SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases for the global marketplace in collaboration with local partners, is pleased to announce that pre-clinical drug development work is beginning at Menlo Park, California based Stanford Research International, (SRI), on its novel and proprietary second generation CFTR (cystic fibrosis transmembrane conductance regulator) inhibitors for the treatment of secretory diarrhea. These activities are being done using pre-clinical resources offered by the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The activities conducted by SRI are focused on providing key data towards supporting the filing of an Investigational New Drug (IND) application for the novel CFTR inhibitor.
